Precision Pharmacotherapy for Childhood Obesity: Molecular Targets Beyond Single GLP-1 Receptor Agonism and a Framework for Disease Modification
- 1Division of Endocrinology, Department of Pediatric Medicine, Sidra Medicine, Doha PO BOX 26999, Qatar
Abstract
Childhood obesity is a heterogeneous chronic disease shaped by genetic susceptibility, neuroendocrine signaling, energy homeostasis, adipose dysfunction, insulin resistance, and environmental exposure. Glucagon-like peptide-1 (GLP-1) receptor agonists have markedly improved treatment efficacy, but heterogeneous response, weight recurrence after withdrawal, residual organ risk, and limited long-term pediatric data expose the limitations of a single-pathway, weight-centered model. This narrative review integrates the molecular rationale and clinical evidence for precision pharmacotherapy beyond single GLP-1 receptor agonism. It examines glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 and GLP-1/glucagon co-agonism, triple agonism, amylin combinations, fibroblast growth factor 21 (FGF21) analogues, leptin replacement, and melanocortin-4 receptor (MC4R) agonism, separating established pediatric evidence from adult proof-of-concept and preclinical inference. Genotype-directed treatment for monogenic and syndromic obesity and lesion-directed treatment for acquired hypothalamic obesity provide the clearest examples of causal pathway correction. For common obesity, treatment selection should integrate developmental stage, hyperphagia, insulin resistance, ectopic fat, body composition, genetic context, treatment burden, and early response. Disease modification should be evaluated across growth, puberty, bone and lean tissue, beta cell and hepatic health, physical function, psychosocial well-being, safety, and durability. A dynamic cycle of phenotyping, mechanism-based treatment, multidomain monitoring, adaptation, and longitudinal re-phenotyping may improve the clinical relevance of pediatric obesity care.
Related
- Precision Therapeutics for Monogenic Epilepsies: From Molecular Mechanisms to Disease Modification in Developmental and Epileptic Encephalopathies and Neurodevelopmental Disorders with Epilepsy
- The promise and limits of patient-reported outcomes in molecular tumor board-guided care: toward a framework for patient-centered precision oncology.
- Corticosteroids in septic shock: mechanisms, heterogeneous treatment effects, and trajectory-guided precision pharmacotherapy
- Diabesity: an old term, a modern challenge — multi-omics and precision anti-obesity pharmacotherapy in type 2 diabetes
- Continuous glucose monitoring after discontinuation of incretin-based obesity pharmacotherapy: indirect evidence and a research framework for metabolic stability and weight maintenance
BibTeX
@article{dauleh2026precision,
title = {{Precision Pharmacotherapy for Childhood Obesity: Molecular Targets Beyond Single GLP-1 Receptor Agonism and a Framework for Disease Modification}},
author = {Hajar Dauleh and Khalid Hussain},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27209269},
url = {https://www.mdpi.com/1422-0067/27/20/9269},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Precision Pharmacotherapy for Childhood Obesity: Molecular Targets Beyond Single GLP-1 Receptor Agonism and a Framework for Disease Modification
AU - Hajar Dauleh
AU - Khalid Hussain
PY - 2026
DA - 2026/10/19
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27209269
UR - https://www.mdpi.com/1422-0067/27/20/9269
AB - Childhood obesity is a heterogeneous chronic disease shaped by genetic susceptibility, neuroendocrine signaling, energy homeostasis, adipose dysfunction, insulin resistance, and environmental exposure. Glucagon-like peptide-1 (GLP-1) receptor agonists have markedly improved treatment efficacy, but heterogeneous response, weight recurrence after withdrawal, residual organ risk, and limited long-term pediatric data expose the limitations of a single-pathway, weight-centered model. This narrative review integrates the molecular rationale and clinical evidence for precision pharmacotherapy beyond single GLP-1 receptor agonism. It examines glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 and GLP-1/glucagon co-agonism, triple agonism, amylin combinations, fibroblast growth factor 21 (FGF21) analogues, leptin replacement, and melanocortin-4 receptor (MC4R) agonism, separating established pediatric evidence from adult proof-of-concept and preclinical inference. Genotype-directed treatment for monogenic and syndromic obesity and lesion-directed treatment for acquired hypothalamic obesity provide the clearest examples of causal pathway correction. For common obesity, treatment selection should integrate developmental stage, hyperphagia, insulin resistance, ectopic fat, body composition, genetic context, treatment burden, and early response. Disease modification should be evaluated across growth, puberty, bone and lean tissue, beta cell and hepatic health, physical function, psychosocial well-being, safety, and durability. A dynamic cycle of phenotyping, mechanism-based treatment, multidomain monitoring, adaptation, and longitudinal re-phenotyping may improve the clinical relevance of pediatric obesity care.
SN - 1422-0067
ER -